Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal ...

Indian equity markets opened on a cautious note, a day after recording a sharp recovery that snapped a six-week losing streak ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

The 20-valent pneumococcal conjugate vaccine (PCV20, or Prevnar 20) produced a non-inferior immune response in adults to the 13-valent vaccine (PCV13, or Prevnar 13), with an adequate safety ...

V116 was non-inferior to PCV20 for the 10 serotypes common to both vaccines (3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, 33F), as assessed by serotype-specific OPA GMTs 30 days post-vaccination.

The study compared VAX-31 to PCV20 in 1,015 healthy adults aged 50 and older. The company has selected VAX-31 to advance to an adult Phase 3 program.

If a person receives PCV15, they may receive a dose of PPSV23 after 1 year. However, this is unnecessary with PCV20 and PCV21. » Learn more: Does Medicare cover pneumonia shots?

About the VAX-31 Phase 1/2 Study The VAX-31 Phase 1/2 clinical study is a randomized, observer-blind, active-controlled, dose-finding clinical study designed to evaluate the safety, tolerability ...